Energy is a significant cost in the production of pharmaceuticals, and therefore reduction in energy usage whilst maintaining quality and compliance is a key driver for many of our clients.
Heating, ventilation and air conditioning (HVAC) within regulated environments is typically responsible for consuming up to 40-80% of a site’s total energy, and it therefore tends to also represent the largest opportunity for improvement. Our team are proven experts in this field, having identified in excess of $50m of savings for our clients from HVAC optimisation alone over the past year.
All of our work is fully quantified, with initial opportunity identification studies looking at likely savings/costs/payback, followed by detailed project development/feasibility in preparation for capital investment request/approval with cost savings and payback periods calculated (as well as CO2 emissions and energy usage reduction). Most of our solutions have a high return on investment, typically with simple paybacks of well under 5 years.
To verify project outcomes and savings, we developed our MEMUTM product, which is a GSM enabled mobile energy monitoring unit which can be deployed anywhere in the world. It picks up readings from wireless sensors (temp, power, fluid flow, humidity, pressure, air flow or any measured input) and calculates the energy expended on virtually any energy consuming plant. Data is uploaded to a website/dashboard portal for viewing energy trends at equipment level.
To find out more about MEMUTM click here.